Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303391 | 0.83 | CDK4 (0.47) | CDK4GRM5 | |
| SCHEMBL12425491 | 0.83 | CDK4 (0.47) | CDK4GRM5 | |
| SCHEMBL12425874 | 0.83 | CDK4 (0.47) | CDK4GRM5 | |
| SCHEMBL2302844 | 0.77 | CDK4 (0.44) | CDK4MAPTPOLBRAB9ACHRNB2 | |
| SCHEMBL2302846 | 0.77 | CDK4 (0.44) | CDK4MAPTPOLBRAB9ACHRNB2 | |
| SCHEMBL736989 | 0.77 | CDK4 (0.43) | CDK4GRM5 | |
| SCHEMBL736268 | 0.77 | CDK4 (0.45) | CDK4GRM5 | |
| SCHEMBL736348 | 0.77 | OPRL1 (0.44) | CDK4GRM5 | |
| SCHEMBL2301340 | 0.75 | MAPT (0.42) | CDK4MAPTPOLBRAB9A | |
| SCHEMBL736627 | 0.74 | CHRNB2 (0.46) | CDK4GRM5CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |